© 2001–2012, Oregon Health & Science
University, Portland, Oregon 97201. All rights reserved.
Bookshelf ID: NBK10527
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
This publication is provided for historical reference only and the information may be out of date.
Drug Class Reviews
Drug Effectiveness Review Project.
Portland (OR): Oregon Health & Science University; 2001-.
The Drug Effectiveness Review Project (DERP) is a collaboration of public entities, the Center for Evidence-based Policy and the Oregon Evidence-based Practice Center, who have joined together to produce systematic, evidence-based reviews of the comparative effectiveness and safety of drugs in many widely used drug classes, and to apply the findings to inform public policy and related activities in local settings.
The DERP project produces systematic literature reviews of drug classes using only the highest quality evidence. Reviews are public and have the following components:
- Key Questions - to focus the review
- Evidence Tables - detailing what research was used in the review
- Draft Report - draft of review - only posted for public commentary during public comment review period
- Final Report - final version of systematic review that incorporates or considers public commentary
Contents
Archived
- Drug Class Review: Targeted Immune Modulators: Final Update 3 ReportKylie J Thaler, Gerald Gartlehner, Christina Kien, Megan G Van Noord, Sujata Thakurta, Roberta C M Wines, Richard A Hansen, and Marian S McDonagh.Portland (OR): Oregon Health & Science University; March 2012.
- Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Update 4 ReportMarian S McDonagh, Kim Peterson, Sujata Thakurta, and Allison Low.Portland (OR): Oregon Health & Science University; December 2011.
- Drug Class Review: Long-Acting Opioid Analgesics: Final Update 6 ReportSusan Carson, Sujata Thakurta, Allison Low, Beth Smith, and Roger Chou.Portland (OR): Oregon Health & Science University; July 2011.
- Drug Class Review: Neuropathic Pain: Final Update 1 ReportShelley Selph, Susan Carson, Rongwei Fu, Sujata Thakurta, Allison Low, and Marian McDonagh.Portland (OR): Oregon Health & Science University; June 2011.
- Drug Class Review: Newer Antiplatelet Agents: Final Update 2 ReportKathy Ketchum, Kim Peterson, Sujata Thakurta, Allison Low, and Marian S McDonagh.Portland (OR): Oregon Health & Science University; June 2011.
- Drug Class Review: Controller Medications for Asthma: Final Update 1 ReportDaniel E Jonas, Roberta C M Wines, Marcy DelMonte, Halle R Amick, Tania M Wilkins, Brett D Einerson, Christine L Schuler, Blake A Wynia, and Betsy Bryant Shilliday.Portland (OR): Oregon Health & Science University; April 2011.
- Drug Class Review: Drugs for Fibromyalgia: Final Original ReportBeth Smith, Kim Peterson, Rochelle Fu, Marian McDonagh, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; April 2011.
- Drug Class Review: Second-Generation Antidepressants: Final Update 5 ReportGerald Gartlehner, Richard A Hansen, Ursula Reichenpfader, Angela Kaminski, Christina Kien, Michaela Strobelberger, Megan Van Noord, Patricia Thieda, Kylie Thaler, and Bradley Gaynes.Portland (OR): Oregon Health & Science University; March 2011.
- Drug Class Review: Disease-Modifying Drugs for Multiple Sclerosis: Single Drug Addendum: Fingolimod: Final Original ReportMarian McDonagh.Portland (OR): Oregon Health & Science University; February 2011.
- Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original ReportDan Jonas, Erin Van Scoyoc, Kate Gerrald, Roberta Wines, Halle Amick, Matthew Triplette, and Thomas Runge.Portland (OR): Oregon Health & Science University; February 2011.
- Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 ReportKim Peterson, Marian McDonagh, Sujata Thakurta, Tracy Dana, Carol Roberts, Roger Chou, and Mark Helfand.Portland (OR): Oregon Health & Science University; November 2010.
- Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 ReportBeth Smith, Susan Carson, Rochelle Fu, Marian McDonagh, Tracy Dana, Benjamin KS Chan, Sujata Thakurta, and Andrew Gibler.Portland (OR): Oregon Health & Science University; August 2010.
- Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 ReportMarian McDonagh, Kim Peterson, Susan Carson, Rochelle Fu, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; July 2010.
- Drug Class Review: Newer Antihistamines: Final Report Update 2Susan Carson, Nancy Lee, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; May 2010.
- Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers: Final ReportSusan Norris, Jessica Weinstein, Kimberly Peterson, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; January 2010.
- Drug Class Review: HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin: Final Report Update 5ME Beth Smith, Nancy J Lee, Elizabeth Haney, and Susan Carson.Portland (OR): Oregon Health & Science University; November 2009.
- Drug Class Review: Targeted Immune Modulators: Final Report Update 2Gerald Gartlehner, Patricia Thieda, Laura C Morgan, Kylie Thaler, Richard A Hansen, and Beth Jonas.Portland (OR): Oregon Health & Science University; November 2009.
- Drug Class Review: Pharmacologic Treatments for Attention Deficit Hyperactivity Disorder: Final Report Update 3Marian S McDonagh, Vivian Christensen, Kim Peterson, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; October 2009.
- Drug Class Review: Beta Adrenergic Blockers: Final Report Update 4Mark Helfand, Kim Peterson, Vivian Christensen, Tracy Dana, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; July 2009.
- Drug Class Review: Triptans: Final Report Update 4Mark Helfand and Kim Peterson.Portland (OR): Oregon Health & Science University; June 2009.
- Drug Class Review: Proton Pump Inhibitors: Final Report Update 5Marian S McDonagh, Susan Carson, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; May 2009.
- Drug Class Review: Agents for Overactive Bladder: Final Report Update 4Marian S McDonagh, Dana Selover, John Santa, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; March 2009.
- Drug Class Review: Newer Antiemetics: Final Report Update 1Kimberly Peterson, Marian McDonagh, Susan Carson, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; January 2009.
- Drug Class Review: Controller Medications for Asthma: Final ReportDaniel E Jonas, Katie Kiser, Betsy Bryant Shilliday, Laura C Morgan, Patricia Thieda, and Daniel Reuland.Portland (OR): Oregon Health & Science University; November 2008.
- Drug Class Review: Antiepileptic Drugs for Indications Other Than Epilepsy: Final Report Update 2Marian McDonagh, Kim Peterson, Nancy Lee, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; October 2008.
- Drug Class Review: Newer Drugs for Insomnia: Final Report Update 2Susan Carson, Marian S McDonagh, Sujata Thakurta, and Po-Yin Yen.Portland (OR): Oregon Health & Science University; October 2008.
- Drug Class Review: Quick-relief Medications for Asthma: Final Report Update 1Susan L Norris, Tarra K McNally, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; October 2008.
- Drug Class Review: Second Generation Antidepressants: Final Report Update 4Gerald Gartlehner, Laura C Morgan, Patricia Thieda, Kylie Thaler, Richard A Hansen, Bradley Gaynes, Kathleen N Lohr, and Timothy S Carey.Portland (OR): Oregon Health & Science University; October 2008.
- Drug Class Review: Topical Calcineurin Inhibitors: Final ReportNancy J Lee, Marian McDonagh, Benjamin Chan, Kimberly Peterson, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; October 2008.
- Drug Class Review: Newer Drugs for the Treatment of Diabetes Mellitus: Final ReportSusan L Norris, Nancy J Lee, Susan Severance, Sujata Thakurta, and Benjamin Chan.Portland (OR): Oregon Health & Science University; August 2008.
- Drug Class Review: Thiazolidinediones: Final Report Update 1Susan L Norris, Susan Carson, Sujata Thakurta, and Benjamin KS Chan.Portland (OR): Oregon Health & Science University; August 2008.
- Drug Class Review: Atypical Antipsychotic Drugs: Final Report Update 2Marian S McDonagh, Kim Peterson, Susan Carson, Benjamin Chan, and Sujata Thakurta.Portland, (OR): Oregon Health & Science University; June 2008.
- Drug Class Review: Nasal Corticosteroids: Final Report Update 1Dana Selover, Tracy Dana, Colleen Smith, and Kim Peterson.Portland (OR): Oregon Health & Science University; June 2008.
- Drug Class Review: Long-Acting Opioid Analgesics: Final Report Update 5Roger Chou and Susan Carson.Portland (OR): Oregon Health & Science University; April 2008.
- Drug Class Review on Pharmacologic Treatments for ADHD: Final ReportMarian S McDonagh, Kim Peterson, Tracy Dana, and Sujata Thakurta.Portland (OR): Oregon Health & Science University; December 2007.
- Drug Class Review: Drugs for Neuropathic Pain: Final ReportRoger Chou, Susan L Norris, Susan Carson, and Benjamin KS Chan.Portland (OR): Oregon Health & Science University; October 2007.
- Drug Class Review: Fixed Dose Combination Drug Products for the Treatment of Type 2 Diabetes and Hyperlipidemia: Final ReportMarian McDonagh, Kim Peterson, Sujata G Thakurta, and Tracy Dana.Portland (OR): Oregon Health & Science University; October 2007.
- Drug Class Review: Hormone Therapy for Postmenopausal Women or Women in the Menopausal Transition Stage: Final Report Update # 3Heidi D Nelson, Peggy Nygren, Michele Freeman, and Benjamin KS Chan.Portland, (OR): Oregon Health & Science University; October 2007.
- Drug Class Review on Beta Adrenergic Blockers: Final ReportMark Helfand, Kim Peterson, and Tracy Dana.Portland (OR): Oregon Health & Science University; September 2007.
- Drug Class Review: Constipation Drugs: Final ReportGerald Gartlehner, Daniel E Jonas, Laura C Morgan, Yehuda Ringel, Richard A Hansen, Curtis M Bryant, and Tim Carey.Portland (OR): Oregon Health & Science University; September 2007.
- Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final ReportMarian McDonagh, Tracy Dana, Benjamin KS Chan, Sujata Thakurta, and Andrew Gibler.Portland (OR): Oregon Health & Science University; July 2007.
- Drug Class Review: Pegylated Interferons for Chronic Hepatitis C Infection: Final ReportRoger Chou, Susan Carson, Benjamin KS Chan, and Byron Care.Portland (OR): Oregon Health & Science University; May 2007.
- Drug Class Review: Newer Antiplatelet Agents: Final Report Update 1Janet H Dailey, Peter Glassman, Marian McDonagh, Kim Peterson, Marika Suttorp, and Susan Chen.Portland (OR): Oregon Health & Science University; April 2007.
- Drug Class Review on Targeted Immune Modulators: Final ReportGerald Gartlehner, Richard A Hansen, Patricia Thieda, Beth Jonas, Kathleen N Lohr, and Tim Carey.Portland (OR): Oregon Health & Science University; January 2007.
- Drug Class Review: Beta2-Agonists: Final ReportSusan L Norris, Po-Yin Yen, Tracy L Dana, Byron R Care, and Brittany U Burda.Portland (OR): Oregon Health & Science University; November 2006.
- Drug Class Review: Cyclo-oxygenase (COX)-2 Inhibitors and Non-steroidal Anti-inflammatory Drugs (NSAIDs): Final Report Update 3Roger Chou, Mark Helfand, Kim Peterson, Tracy Dana, and Carol Roberts.Portland (OR): Oregon Health & Science University; November 2006.
- Drug Class Review on HMG-CoA Reductase Inhibitors (Statins): Final ReportMark Helfand, Susan Carson, and Cathy Kelley.Portland (OR): Oregon Health & Science University; August 2006.
- Drug Class Review on Newer Drugs for Insomnia: Final ReportSusan Carson, Po-Yin Yen, and Marian S McDonagh.Portland (OR): Oregon Health & Science University; July 2006.
- Drug Class Review: Proton Pump Inhibitors: Final ReportMarian S McDonagh and Susan Carson.Portland (OR): Oregon Health & Science University; July 2006.
- Drug Class Review: Alzheimer's Drugs: Final ReportRichard A Hansen, Gerald Gartlehner, Daniel J Kaufer, Kathleen N Lohr, and Tim Carey.Portland (OR): Oregon Health & Science University; June 2006.
- Drug Class Review: Newer Antihistamines: Final ReportOregon Evidence-based Practice Center .Portland (OR): Oregon Health & Science University; April 2006.
- Drug Class Review on Second Generation Antidepressants: Final ReportGerald Gartlehner, Richard A Hansen, Leila Kahwati, Kathleen N Lohr, Bradley Gaynes, and Tim Carey.Portland (OR): Oregon Health & Science University; March 2006.
- Drug Class Review on Newer Antiemetics: Final ReportKimberly Peterson, Marian McDonagh, Susan Carson, and Sarah Lopez.Portland (OR): Oregon Health & Science University; January 2006.
- Drug Class Review: Inhaled Corticosteroids: Final ReportRichard A Hansen, Gerald Gartlehner, Kathleen N Lohr, Shannon Carson, and Timothy Carey.Portland (OR): Oregon Health & Science University; January 2006.
- Drug Class Review on Agents for Overactive Bladder: Final ReportMarian S McDonagh, Dana Selover, John Santa, and Sarah Lopez.Portland (OR): Oregon Health & Science University; December 2005.
- Drug Class Review on Triptans: Final Report Update 3Mark Helfand and Kim Peterson.Portland (OR): Oregon Health & Science University; November 2005.
- Drug Class Review: Oral Hypoglycemics: Final ReportChris Chandler, Roger Chou, and Mark Helfand.Portland (OR): Oregon Health & Science University; May 2005.
- Drug Class Review: Skeletal Muscle Relaxants: Final ReportRoger Chou and Kim Peterson.Portland (OR): Oregon Health & Science University; May 2005.
- Drug Class Review: Calcium Channel Blockers: Final ReportMarian S McDonagh, Karen B Eden, and Kim Peterson.Portland (OR): Oregon Health & Science University; March 2005.
- Drug Class ReviewsDrug Class Reviews
Your browsing activity is empty.
Activity recording is turned off.
See more...